Aura M. Ramirez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aura M. Ramirez has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Anthony J. Griswold
John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine Miami Florida USA
2 shared publications- Briseida E. Feliciano-Astacio
Universidad Central del Caribe Bayamón Puerto Rico
2 shared publications Brooke A. DeRosa
John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine Miami Florida USA
2 shared publicationsDerek J. Van Booven
John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine Miami Florida USA
2 shared publications- Derek Michael Dykxhoorn
John T. Macdonald Foundation Department of Human Genetics and, the John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA
2 shared publications - Farid Rajabli
John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publications
Latest Publications
- Open Access
- 26 February 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2) , e70031
Comparing Alzheimer's genes in African, European, and Amerindian induced pluripotent stem cell–derived microglia
INTRODUCTION: Genome‐wide association studies (GWAS) studies in Alzheimer's disease (AD) demonstrate ancestry‐specific loci. Previous studies in the regulatory architecture have only been conducted in Europeans (EUs), thus studies in additional ancestries are needed. Given the prevalence of AD genes expressed in microglia, we initiated our studies in induced pluripotent stem cell (iPSC) ‐derived microglia. METHODS: We created iPSC‐derived microglia from 13 individuals of either high Amerindian (AI), African (AF), or EU global ancestry, including both AD and controls. RNA‐seq, ATAC‐seq, and pathway analyses were compared between ancestries in both AD and non‐AD genes. RESULTS: Twelve AD genes were differentially expressed genes (DEGs) and/or accessible between ancestries, including ABI3 , CTSB , and MS4A6A . A total of 5% of all genes had differential ancestral expression, but differences in accessibility were less than 1%. The DEGs were enriched in known AD pathways. DISCUSSION: This resource will be valuable in evaluating AD in admixed populations and other neurological disorders and understanding the AD risk differences between populations. Highlights: First comparison of the genomics of AI, AF, and EU microglia. Report differences in expression and accessibility of AD genes between ancestries. Ancestral expression differences are greater than differences in accessibility. Good transcriptome correlation was seen between brain and iPSC‐derived microglia. Differentially expressed AD genes were in known AD pathways.
- 26 February 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2) , e70031
Open AccessComparing Alzheimer's genes in African, European, and Amerindian induced pluripotent stem cell–derived microglia
INTRODUCTION: Genome‐wide association studies (GWAS) studies in Alzheimer's disease (AD) demonstrate ancestry‐specific loci. Previous studies in the regulatory architecture have only been conducted in Europeans (EUs), thus studies in additional ancestries are needed. Given the prevalence of AD genes expressed in microglia, we initiated our studies in induced pluripotent stem cell (iPSC) ‐derived microglia. METHODS: We created iPSC‐derived microglia from 13 individuals of either high Amerindian (AI), African (AF), or EU global ancestry, including both AD and controls. RNA‐seq, ATAC‐seq, and pathway analyses were compared between ancestries in both AD and non‐AD genes. RESULTS: Twelve AD genes were differentially expressed genes (DEGs) and/or accessible between ancestries, including ABI3 , CTSB , and MS4A6A . A total of 5% of all genes had differential ancestral expression, but differences in accessibility were less than 1%. The DEGs were enriched in known AD pathways. DISCUSSION: This resource will be valuable in evaluating AD in admixed populations and other neurological disorders and understanding the AD risk differences between populations. Highlights: First comparison of the genomics of AI, AF, and EU microglia. Report differences in expression and accessibility of AD genes between ancestries. Ancestral expression differences are greater than differences in accessibility. Good transcriptome correlation was seen between brain and iPSC‐derived microglia. Differentially expressed AD genes were in known AD pathways.
- Open Access
Gene expression and chromatin accessibility comparison in iPSC-derived microglia in African, European, and Amerindian genomes in Alzheimer’s patients and controls
Alzheimer’s disease (AD) risk differs between population groups, with African Americans and Hispanics being the most affected groups compared to non-Hispanic Whites. Genetic factors contribute significant risk to AD, but the genetic regulatory architectures (GRA) have primarily been studied in Europeans. Many AD genes are expressed in microglia; thus, we explored the impact of genetic ancestry (Amerindian (AI), African (AF), and European (EU)) on the GRA in iPSC-derived microglia from 13 individuals (∼4 each with high global ancestry, AD and controls) through ATAC-seq and RNA-seq analyses. We identified several differentially accessible and expressed genes (2 and 10 AD-related, respectively) between ancestry groups. We also found a high correlation between the transcriptomes of iPSC-derived and brain microglia, supporting their use in human studies. This study provides valuable insights into genetically diverse microglia beyond the analysis of AD.
Open AccessGene expression and chromatin accessibility comparison in iPSC-derived microglia in African, European, and Amerindian genomes in Alzheimer’s patients and controls
Alzheimer’s disease (AD) risk differs between population groups, with African Americans and Hispanics being the most affected groups compared to non-Hispanic Whites. Genetic factors contribute significant risk to AD, but the genetic regulatory architectures (GRA) have primarily been studied in Europeans. Many AD genes are expressed in microglia; thus, we explored the impact of genetic ancestry (Amerindian (AI), African (AF), and European (EU)) on the GRA in iPSC-derived microglia from 13 individuals (∼4 each with high global ancestry, AD and controls) through ATAC-seq and RNA-seq analyses. We identified several differentially accessible and expressed genes (2 and 10 AD-related, respectively) between ancestry groups. We also found a high correlation between the transcriptomes of iPSC-derived and brain microglia, supporting their use in human studies. This study provides valuable insights into genetically diverse microglia beyond the analysis of AD.
- Open Access
- 13 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Evaluation of a bone filler scaffold for local antibiotic delivery to prevent Staphylococcus aureus infection in a contaminated bone defect
We previously reported the development of an osteogenic bone filler scaffold consisting of degradable polyurethane, hydroxyapatite, and decellularized bovine bone particles. The current study was aimed at evaluating the use of this scaffold as a means of local antibiotic delivery to prevent infection in a bone defect contaminated with Staphylococcus aureus. We evaluated two scaffold formulations with the same component ratios but differing overall porosity and surface area. Studies with vancomycin, daptomycin, and gentamicin confirmed that antibiotic uptake was concentration dependent and that increased porosity correlated with increased uptake and prolonged antibiotic release. We also demonstrate that vancomycin can be passively loaded into either formulation in sufficient concentration to prevent infection in a rabbit model of a contaminated segmental bone defect. Moreover, even in those few cases in which complete eradication was not achieved, the number of viable bacteria in the bone was significantly reduced by treatment and there was no radiographic evidence of osteomyelitis. Radiographs and microcomputed tomography (µCT) analysis from the in vivo studies also suggested that the addition of vancomycin did not have any significant effect on the scaffold itself. These results demonstrate the potential utility of our bone regeneration scaffold for local antibiotic delivery to prevent infection in contaminated bone defects.
- 13 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Open AccessEvaluation of a bone filler scaffold for local antibiotic delivery to prevent Staphylococcus aureus infection in a contaminated bone defect
We previously reported the development of an osteogenic bone filler scaffold consisting of degradable polyurethane, hydroxyapatite, and decellularized bovine bone particles. The current study was aimed at evaluating the use of this scaffold as a means of local antibiotic delivery to prevent infection in a bone defect contaminated with Staphylococcus aureus. We evaluated two scaffold formulations with the same component ratios but differing overall porosity and surface area. Studies with vancomycin, daptomycin, and gentamicin confirmed that antibiotic uptake was concentration dependent and that increased porosity correlated with increased uptake and prolonged antibiotic release. We also demonstrate that vancomycin can be passively loaded into either formulation in sufficient concentration to prevent infection in a rabbit model of a contaminated segmental bone defect. Moreover, even in those few cases in which complete eradication was not achieved, the number of viable bacteria in the bone was significantly reduced by treatment and there was no radiographic evidence of osteomyelitis. Radiographs and microcomputed tomography (µCT) analysis from the in vivo studies also suggested that the addition of vancomycin did not have any significant effect on the scaffold itself. These results demonstrate the potential utility of our bone regeneration scaffold for local antibiotic delivery to prevent infection in contaminated bone defects.